Rani Therapeutics Holdings Stock EBITDA
| RANI Stock | USD 2.08 0.04 1.96% |
Rani Therapeutics Holdings fundamentals help investors to digest information that contributes to Rani Therapeutics' financial success or failures. It also enables traders to predict the movement of Rani Stock. The fundamental analysis module provides a way to measure Rani Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Rani Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | -65.3 M | -68.5 M |
Rani | EBITDA |
Rani Therapeutics Holdings Company EBITDA Analysis
Rani Therapeutics' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Rani Therapeutics EBITDA | (65.28 M) |
Most of Rani Therapeutics' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Rani Therapeutics Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Rani EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for Rani Therapeutics is extremely important. It helps to project a fair market value of Rani Stock properly, considering its historical fundamentals such as EBITDA. Since Rani Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Rani Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Rani Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
Rani Ebitda
Ebitda |
|
According to the company disclosure, Rani Therapeutics Holdings reported earnings before interest,tax, depreciation and amortization of (65.28 Million). This is 107.44% lower than that of the Biotechnology sector and 165.18% lower than that of the Health Care industry. The ebitda for all United States stocks is 101.67% higher than that of the company.
Rani EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Rani Therapeutics' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Rani Therapeutics could also be used in its relative valuation, which is a method of valuing Rani Therapeutics by comparing valuation metrics of similar companies.Rani Therapeutics is currently under evaluation in ebitda category among its peers.
Rani Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Rani Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Rani Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Rani Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Rani Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Rani Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Rani Therapeutics' value.| Shares | Lasry Marc | 2024-06-30 | 62.9 K | Motco | 2024-09-30 | 48.1 K | State Street Corp | 2024-06-30 | 42 K | Renaissance Technologies Corp | 2024-09-30 | 33.2 K | Brown Advisory Holdings Inc | 2024-09-30 | 32.9 K | Citadel Advisors Llc | 2024-09-30 | 26.9 K | Marshall Wace Asset Management Ltd | 2024-06-30 | 21.2 K | Lafayette Investments, Inc. | 2024-06-30 | 19.9 K | Tower Research Capital Llc | 2024-06-30 | 14.4 K | Armistice Capital, Llc | 2024-09-30 | 2.6 M | Vanguard Group Inc | 2024-09-30 | 709.8 K |
Rani Fundamentals
| Return On Equity | -2.25 | ||||
| Return On Asset | -0.57 | ||||
| Current Valuation | 72.62 M | ||||
| Shares Outstanding | 33.31 M | ||||
| Shares Owned By Insiders | 30.61 % | ||||
| Shares Owned By Institutions | 19.58 % | ||||
| Number Of Shares Shorted | 1.49 M | ||||
| Price To Book | 22.21 X | ||||
| Price To Sales | 313.17 X | ||||
| Gross Profit | 2.72 M | ||||
| EBITDA | (65.28 M) | ||||
| Net Income | (33.97 M) | ||||
| Cash And Equivalents | 98.17 M | ||||
| Cash Per Share | 3.97 X | ||||
| Total Debt | 30.1 M | ||||
| Debt To Equity | 0.18 % | ||||
| Current Ratio | 14.02 X | ||||
| Book Value Per Share | 0.49 X | ||||
| Cash Flow From Operations | (51.24 M) | ||||
| Short Ratio | 0.36 X | ||||
| Earnings Per Share | (1.05) X | ||||
| Price To Earnings To Growth | 0.68 X | ||||
| Target Price | 11.5 | ||||
| Number Of Employees | 140 | ||||
| Beta | 0.11 | ||||
| Market Capitalization | 121.78 M | ||||
| Total Asset | 57.92 M | ||||
| Retained Earnings | (72.89 M) | ||||
| Working Capital | 42.86 M | ||||
| Net Asset | 57.92 M |
About Rani Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Rani Therapeutics Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rani Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rani Therapeutics Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Rani Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Rani Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Rani Therapeutics Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Rani Therapeutics Holdings Stock:Check out Rani Therapeutics Piotroski F Score and Rani Therapeutics Altman Z Score analysis. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rani Therapeutics. If investors know Rani will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rani Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.05) | Quarterly Revenue Growth (1.00) | Return On Assets (0.57) | Return On Equity (2.25) |
The market value of Rani Therapeutics is measured differently than its book value, which is the value of Rani that is recorded on the company's balance sheet. Investors also form their own opinion of Rani Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Rani Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rani Therapeutics' market value can be influenced by many factors that don't directly affect Rani Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rani Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rani Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rani Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.